- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Fischer enjoys record fourth quarter
Record fourth quarter sales and earnings helped Fischer Imagingfinish its 1995 fiscal year with a flourish. The Denver-based x-ray vendor reported fourth-quarter earnings(end-December) of $1.5 million and $23 million in sales, bothcompany records.
Record fourth quarter sales and earnings helped Fischer Imagingfinish its 1995 fiscal year with a flourish.
The Denver-based x-ray vendor reported fourth-quarter earnings(end-December) of $1.5 million and $23 million in sales, bothcompany records. Revenues were up 25% from the same period of1994.
For the 1995 fiscal year, Fischer reported net earnings of$2.3 million on the strength of $76.8 million in sales. The performancewas a notable improvement over fiscal 1994, when the company lost$5.6 million on sales of $68.5 million. CEO Morgan Nields attributedthe turnaround to an improved sales mix and global sales growth,as well as gains made through OEM deals and internal cost-cuttingmeasures.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
